{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:13:00Z","timestamp":1787670780953,"version":"build-2736575974"},"reference-count":45,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T00:00:00Z","timestamp":1603238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Bipolar disorder is a chronic and remitting mental illness. Antidepressants are not effective in treating acute bipolar depression, and antipsychotic drugs used in the treatment of bipolar depression cause frequent side effects. This situation justifies the search for new drugs as well as the repurposing of drugs used in other indications. In an open and naturalistic serious case study, 4 patients diagnosed with bipolar I disorder, chronically treated with a mood stabilizer, in whom at least two antidepressants were ineffective in the depressive phase, were treated with amantadine. The woman received 100 mg\/day and 3 men received the target dose of 200 mg\/day. All patients treated with amantadine improved their depressive symptoms after 1 week of treatment. None of them experienced side effects or manic switch. To reduce the risk of a manic switch, the treatment with amantadine was discontinued 2 weeks after the improvement of depressive symptoms, and no recurrence of depressive symptoms was observed. Amantadine may be a further therapeutic option for the treatment of acute bipolar depression. The drug in this indication may act quickly and be well tolerated. Confirmation of the antidepressant efficacy of amantadine in this indication requires replication of the results and conducting clinical trials.<\/jats:p>","DOI":"10.3390\/ph13100326","type":"journal-article","created":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T10:14:22Z","timestamp":1603275262000},"page":"326","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Possibility of a New Indication for Amantadine in the Treatment of Bipolar Depression\u2014Case Series Study"],"prefix":"10.3390","volume":"13","author":[{"given":"Marek","family":"Krzystanek","sequence":"first","affiliation":[{"name":"Clinic of Psychiatric Rehabilitation, Department of Psychiatry and Psychotherapy, Faculty of Medical Sciences, Medical University of Silesia in Katowice, Zio\u0142owa 45\/47, 40-635 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Pa\u0142asz","sequence":"additional","affiliation":[{"name":"Department of Histology, Faculty of Medical Sciences, Medical University of Silesia in Katowice, Medyk\u00f3w 18, 40-752 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1080\/03007995.2019.1636017","article-title":"Bipolar depression: The clinical characteristics and unmet needs of a complex disorder","volume":"35","author":"McIntyre","year":"2019","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/jclp.20360","article-title":"Bipolar disorder: Causes, contexts, and treatments","volume":"63","author":"Leahy","year":"2007","journal-title":"J. Clin. Psychol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Kraepelin, E. (1921). Manic Depressive Insanity and Paranoia, Livingstone.","DOI":"10.1097\/00005053-192104000-00057"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2174\/1570159X14666160606210811","article-title":"Depression and Mania in Bipolar Disorder","volume":"15","author":"Tondo","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.psc.2015.09.001","article-title":"Treatment of Bipolar Depression: Evolving Recommendations","volume":"39","author":"Post","year":"2016","journal-title":"Psychiatr. Clin. North Am."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/acps.12712","article-title":"Dopaminergic agents in the treatment of bipolar depression: A systematic review and meta-analysis","volume":"135","author":"Szmulewicz","year":"2017","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1590\/1516-4446-2017-2393","article-title":"Potential antidepressant effect of amantadine: A review of preclinical studies and clinical trials","volume":"40","author":"Vital","year":"2018","journal-title":"Braz. J. Psychiatry"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0006-8993(94)90821-4","article-title":"Amantadine increases the extracellular dopamine levels in the striatum by re-uptake inhibition and by N-methyl-D-aspartate antagonism","volume":"662","author":"Mizoguchi","year":"1994","journal-title":"Brain Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1523\/JNEUROSCI.4262-04.2005","article-title":"Amantadine inhibits NMDA receptors by accelerating channel closure during channel block","volume":"25","author":"Blanpied","year":"2005","journal-title":"J. Neurosci."},{"key":"ref_10","first-page":"55","article-title":"Amantadine: A review of use in child and adolescent psychiatry","volume":"22","author":"Hosenbocus","year":"2013","journal-title":"J. Can. Acad. Child Adolesc. Psychiatry"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1055\/s-2007-979191","article-title":"Possible use of amantadine in depression","volume":"32","author":"Huber","year":"1999","journal-title":"Pharmacopsychiatry"},{"key":"ref_12","first-page":"257","article-title":"Effect of combined treatment with imipramine and amantadine on the central dopamine D2 and D3 receptors in rats","volume":"54","author":"Dlaboga","year":"2003","journal-title":"Physiol. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0006-8993(00)02339-8","article-title":"Opposite effects of glutamate antagonists and antiparkinsonian drugs on the activities of DOPA decarboxylase and 5-HTP decarboxylase in the rat brain","volume":"868","author":"Fisher","year":"2000","journal-title":"Brain Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1046\/j.1471-4159.1995.64020614.x","article-title":"Regional variations in the pharmacology of NMDA receptor channel blockers: Implications for therapeutic potential","volume":"64","author":"Porter","year":"1995","journal-title":"J. Neurochem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.bbr.2014.10.037","article-title":"Amantadine preserves dopamine level and attenuates depression-like behawior induced by traumatic brain injury in rats","volume":"279","author":"Tan","year":"2015","journal-title":"Behav. Brain Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.pbb.2018.12.010","article-title":"Amantadine enhances nigrostriatal and mesolimbic dopamine function in the rat brain in relation to motor and exploratory activity","volume":"179","author":"Nikolaus","year":"2019","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.pnpbp.2015.02.015","article-title":"Role of calcium, glutamate and NMDA in major depression and therapeutic application","volume":"64","author":"Deutschenbaur","year":"2016","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1176\/appi.ajp.2015.15040465","article-title":"APA Council of Research Task Force on Novel Biomarkers and Treatments Ketamine and other NMDA antagonists: Early clinical trials and possible mechanisms in depression","volume":"172","author":"Newport","year":"2015","journal-title":"Am. J. Psychiatry"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1590\/S1516-44462005000300016","article-title":"Glutamate modulators as novel interventions for mood disorders","volume":"27","author":"Mathew","year":"2005","journal-title":"Revista Brasiliera Psiquiatria"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0014-2999(00)00573-2","article-title":"Increased dopamine uptake in striatal synaptosomes after treatment of rats with amantadine","volume":"403","author":"Page","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.psychres.2014.10.028","article-title":"Ketamine and other potential glutamate antidepressants","volume":"225","author":"Dutta","year":"2015","journal-title":"Psychiatry Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1600-0773.1993.tb01351.x","article-title":"Potential antidepressive properties of amantadine, memantine and bifemelane","volume":"72","author":"Moryl","year":"1993","journal-title":"Pharmacol. Toxicol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1734-1140(09)70150-1","article-title":"Effect of repeated co-treatment with fluoxetine and amantadine on the behavioral reactivity of the central dopamine and serotonin system in rats","volume":"61","author":"Skuza","year":"2009","journal-title":"Pharmacol. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1111\/j.0953-816X.2004.03297.x","article-title":"Involvement of the sigma 1 receptor in the modulation of dopaminergic transmission by amantadine","volume":"19","author":"Peeters","year":"2004","journal-title":"Eur. J. Neurosci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0304-3940(93)90362-O","article-title":"Affinity of 1-aminoadamantanes for the sigma binding site in post-mortem human frontal cortex","volume":"163","author":"Kornhuber","year":"1993","journal-title":"Neurosci. Lett."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1124\/jpet.102.043398","article-title":"Sigma1 receptor agonist-mediated regulation of N-methyl-D-aspartate-stimulated [3H]dopamine release is dependent upon protein kinase C","volume":"304","author":"Nuwayhid","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.euroneuro.2007.02.007","article-title":"Novel sigma (sigma) receptor agonists produce antidepressant-like effects in mice","volume":"17","author":"Wang","year":"2007","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0014-2999(96)00254-3","article-title":"Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain","volume":"307","author":"Narita","year":"1996","journal-title":"Eur. J. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0014-2999(90)90139-W","article-title":"Clorgyline displays high affinity for \u03c3-binding sites in C57BL\/6 mouse brain","volume":"176","author":"Itzhak","year":"1990","journal-title":"Eur. J. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.nbd.2016.07.010","article-title":"Brain-derived neurotrophic factor in mood disorders and antidepressant treatments","volume":"97","author":"Castren","year":"2017","journal-title":"Neurobiol. Dis."},{"key":"ref_31","first-page":"817","article-title":"Repeated co-treatment with fluoxetine and amantadine induces brain-derived neurotrophic factor gene expression in rats","volume":"60","author":"Skuza","year":"2008","journal-title":"Pharmacol. Rep."},{"key":"ref_32","first-page":"219","article-title":"Repeated co-treatment with imipramine and amantadine induces hippocampal brain-derived neurotrophic factor gene expression in rats","volume":"58","author":"Skuza","year":"2007","journal-title":"Physiol. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.pharep.2017.12.007","article-title":"Effectiveness of memantine on depression-like behavior, memory deficits and brain mRNA levels of BDNF and TrkB in rats subjected to repeated unpredictable stress","volume":"70","author":"Amidfar","year":"2018","journal-title":"Pharmacol. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"112432","DOI":"10.1016\/j.bbr.2019.112432","article-title":"Amantadine exerts anxiolytic like effect in mice: Evidences for the involvement of nitrergic and GABAergic signaling pathways","volume":"380","author":"Walia","year":"2020","journal-title":"Behav. Brain Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1600-0447.2007.01058.x","article-title":"Dopamine dysregulation syndrome: Implications for a dopamine hypothesis of bipolar disorder","volume":"434","author":"Berk","year":"2007","journal-title":"Acta Psychiatrica Scandinavica Suppl."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Van Rossum, I., Tenback, D., and van Os, J. (2009). Bipolar disorder and dopamine dysfunction: An indirect approach focusing on tardive movement syndromes in a naturalistic setting. BMC Psychiatry, 9.","DOI":"10.1186\/1471-244X-9-16"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0140-6736(71)90153-X","article-title":"Amantadine in depression","volume":"2","author":"Vale","year":"1971","journal-title":"Lancet"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/BF00567008","article-title":"Amantadine in depression: Relationship between behavioral effects and plasma levels","volume":"5","author":"Rizzo","year":"1973","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_39","first-page":"778","article-title":"Amantadine as an additive treatment in patients suffering from drug-resistant unipolar depression","volume":"59","author":"Skuza","year":"2007","journal-title":"Pharmacol. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00004850-200303000-00005","article-title":"Amantadine as augmentation therapy in the management of treatment-resistant depression","volume":"18","author":"Stryjer","year":"2003","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1034\/j.1399-5618.2000.020110.x","article-title":"Amantadine in depressive patients with Borna disease virus (BDV) infection: An open trial","volume":"2","author":"Dietrich","year":"2000","journal-title":"Bipolar Disord."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1001\/jama.2016.3445","article-title":"Treatment indications for antidepressants prescribed in primary care in Quebec, Canada, 2006\u20132015","volume":"315","author":"Wong","year":"2016","journal-title":"JAMA"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"172732","DOI":"10.1016\/j.ejphar.2019.172732","article-title":"Off-label uses of drugs for depression","volume":"865","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1590\/S1516-44462010000400029","article-title":"Mania switch induced by amantadine in bipolar disorder: Report of three cases","volume":"32","author":"Gama","year":"2010","journal-title":"Braz. J. Psychiatry"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/13\/10\/326\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:25:19Z","timestamp":1760178319000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/13\/10\/326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,21]]},"references-count":45,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10]]}},"alternative-id":["ph13100326"],"URL":"https:\/\/doi.org\/10.3390\/ph13100326","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,21]]}}}